



Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency

Thomas Gille^{1,2} and Pierantonio Laveneziana^{3,4}

Number 11 in the Series “Ventilatory efficiency and its clinical prognostic value in cardiorespiratory disorders”

Edited by Pierantonio Laveneziana and Paolo Palange

¹Université Sorbonne Paris Nord (USPN), INSERM, UMR 1272 Hypoxia & the Lung, UFR SMBH Léonard de Vinci, Bobigny, France.

²Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalo-Universitaire Paris-Seine-Saint-Denis (GHUPSSD), Hôpital Avicenne, Service de Physiologie et Explorations Fonctionnelles du Département Médico-Universitaire NARVAL, Bobigny, France.

³Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France. ⁴Assistance Publique - Hôpitaux de Paris (AP-HP), Groupe Hospitalier Universitaire APHP-Sorbonne Université, sites Pitié-Salpêtrière, Saint-Antoine et Tenon, Service des Explorations Fonctionnelles de la Respiration, de l'Exercice et de la Dyspnée (Département R3S), Paris, France.

Corresponding author: Thomas Gille (thomas.gille@aphp.fr)



Shareable abstract (@ERSpublications)

Ventilatory inefficiency, as defined by an abnormally increased minute ventilation/carbon dioxide production relationship during cardiopulmonary exercise testing, has diagnostic and prognostic implications in the management of ILDs <https://bit.ly/3vFnyhq>

Cite this article as: Gille T, Laveneziana P. Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency. *Eur Respir Rev* 2021; 30: 200355 [DOI: 10.1183/16000617.0355-2020].

Copyright ©The authors 2021

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 3 Nov 2020
Accepted: 26 May 2021

Abstract

Interstitial lung diseases (ILDs) are diverse parenchymal pulmonary disorders, primarily characterised by alveolar and interstitial inflammation and/or fibrosis, and sharing pathophysiological similarities. Thus, patients generally harbour common respiratory symptoms, lung function abnormalities and modified exercise adaptation. The most usual and disabling complaint is exertional dyspnoea, frequently responsible for premature exercise interruption. Cardiopulmonary exercise testing (CPET) is increasingly used for the clinical assessment of patients with ILD. This is because exercise performance or dyspnoea on exertion cannot reliably be predicted by resting pulmonary function tests. CPET, therefore, provides an accurate evaluation of functional capacity on an individual basis. CPET can unmask anomalies in the integrated functions of the respiratory, cardiovascular, metabolic, peripheral muscle and neurosensory systems in ILDs. CPET uniquely provides an evaluation of all above aspects and can help clinicians shape ILD patient management. Preliminary evidence suggests that CPET may also generate valuable prognostic information in ILDs and can be used to shed light on the presence of associated pulmonary hypertension. This review aims to provide comprehensive and updated evidence concerning the clinical utility of CPET in ILD patients, with particular focus on the physiological and clinical value of ventilatory efficiency (\dot{V}_E/\dot{V}_{CO_2}).

Introduction

Interstitial lung diseases (ILDs), formerly called diffuse parenchymal lung diseases, are a heterogeneous group of more than 200 rare, non-neoplastic, often chronic disorders. They are primarily characterised by diffuse infiltrates into the lung interstitium. Damage to the lung parenchyma, by various patterns of inflammation and fibrosis, are frequently associated with the involvement of adjacent alveolar epithelium, small distal airways and lung vascular bed, and may result in architectural alterations of the alveolar capillary membrane. Although ILDs regroup distinct pathologies, they share similarities in pathogenesis [1–3]. Thus, patients generally harbour common respiratory symptoms, lung function abnormalities and



modified exercise adaptation. The most usual and disabling complaint is exertional dyspnoea, frequently responsible for premature exercise interruption and important decline in quality of life [4].

Pathological features are worsened during exercise in ILDs. Respiratory, cardiovascular and/or peripheral responses to exercise can all be modified, making cardiopulmonary exercise testing (CPET) an essential tool to untangle the relative contribution of each one [5–9]. Amongst numerous useful variables, the assessment of ventilatory efficiency is of prime importance in CPET interpretation. Ventilatory efficiency is mainly characterised by the relationship between the output of metabolically produced carbon dioxide (\dot{V}_{CO_2}) and the quantity of ventilation (\dot{V}_E) needed to eliminate it. The $\dot{V}_E/\dot{V}_{\text{CO}_2}$ index is called ventilatory equivalent for CO_2 . It mathematically and physiologically depends on CO_2 arterial partial pressure (P_{aCO_2}) and the dead space to tidal volume ratio (V_D/V_T). It can be measured at rest, at its lowest value ($\dot{V}_E/\dot{V}_{\text{CO}_2}$ nadir), at the first ventilatory threshold ($\dot{V}_E/\dot{V}_{\text{CO}_2}$ at VTh, VTh being alternatively called anaerobic threshold) and at peak exercise (peak $\dot{V}_E/\dot{V}_{\text{CO}_2}$). The slope of the relationship can be calculated by linear regression ($\dot{V}_E-\dot{V}_{\text{CO}_2}$ slope). Depending on the authors, the slope is computed from exercise initiation to either the second ventilatory threshold (alternatively called ventilatory compensation point, after which the $\dot{V}_E/\dot{V}_{\text{CO}_2}$ curve steepens) or to peak exercise (on condition that exercise is maximal) [5, 7, 10, 11]. Numerous studies have proven a link between abnormally increased $\dot{V}_E/\dot{V}_{\text{CO}_2}$ (*i.e.* ventilatory inefficiency) and dyspnoea, limited exercise performance and/or poorer outcome in various respiratory or cardiocirculatory conditions, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary hypertension and chronic heart failure [12]. Indeed, multiple mechanisms can interact and result in ventilatory inefficiency: increased physiological dead space, pulmonary vasculopathy, ventilation/perfusion (\dot{V}_A/\dot{Q}) mismatch, exercise-induced hypoxaemia, increased metabolic demand, inappropriate hyperventilation, deconditioning, elevated ventilatory neural drive, sympathetic overstimulation, elevated chemoreceptor or ergoreceptor sensitivity, and metabolic acidosis [5–7, 13–15].

The current review belongs to the *European Respiratory Review* series on “The ventilatory efficiency and its clinical and prognostic value in cardiorespiratory disorders” and provides an up-to-date summary of recent advances concerning the clinical utility of CPET in ILD patients, with particular focus on the physiological and clinical value of ventilatory efficiency.

Epidemiology and classification of ILDs

The incidence and prevalence of ILDs depend on the case counting method and the geographical area. Taking ILDs as a whole, incidence is considered to be around 20–30 cases per 100 000 per year and prevalence around 60–80 cases per 100 000 [16, 17]. A French exhaustive study, performed in a multi-ethnic county of Greater Paris, even found a total crude prevalence of 97.9 per 100 000 [18]. Sarcoidosis, idiopathic pulmonary fibrosis (IPF) and ILDs related to connective tissue diseases (CTDs)/vasculitis represent more than one half of all ILD cases, with respective frequencies depending on age, sex and geographical origin.

Considerable progress was made in the past decades to better understand ILDs. Harmonised nomenclature and diagnostic criteria were provided by the 2002 international consensus classification [19], later updated in 2013 [20]. ILDs can be separated into four groups: 1) ILDs of known aetiology, *e.g.* CTDs/vasculitis, hypersensitivity pneumonitis (HP), iatrogenic ILDs, pneumoconioses; 2) idiopathic interstitial pneumonias (IIPs), *e.g.* IPF, idiopathic non-specific interstitial pneumonia (iNSIP); 3) sarcoidosis and sarcoid-like granulomatous diseases; 4) other forms of ILDs, *e.g.* pulmonary Langerhans cell histiocytosis (PLCH), lymphangioleiomyomatosis (LAM), chronic eosinophilic pneumonia and pulmonary alveolar proteinosis (figure 1). Multidisciplinary discussion is mandatory in diagnostic decision-making, and high-resolution computed tomography (HRCT) is often the cornerstone examination in the process [21, 22]. For example, although surgical lung biopsy is the gold standard to establish a diagnosis of IPF, it is not required in a patient with high clinical likelihood (>60 years old, exclusion of other known cause of ILD) and suggestive HRCT pattern [22, 23].

A complementary categorisation was also proposed, according to patterns of disease behaviour (reversible *versus* irreversible, stable *versus* progressive), which can be useful in most types of ILDs, regardless of the precise diagnosis, to adjust therapeutic goal and monitoring strategy, and set pertinent endpoints in clinical trials [20, 24, 25]. For example, IPF is the very prototype of the “progressive fibrosing ILD” pattern, characterised by irreversible and self-sustaining fibrosis, progressive worsening in dyspnoea and lung function, associated with early mortality. But it can also be encountered in other ILDs such as iNSIP, CTD-related ILD, HP, stage IV sarcoidosis, drug-induced ILD, pneumoconiosis, acute respiratory distress syndrome-related ILD and unclassifiable IIP. All of them could benefit from the same treatments [26, 27]. Level of dyspnoea, lung function at baseline or in the later course of the disease, exercise performances




FIGURE 1 Classification of the main interstitial lung diseases (ILDs). By definition, pulmonary oedema from chronic heart failure, neoplastic diseases (lymphangitis carcinomatosa, lymphoma, lepidic growth adenocarcinoma) and chronic infections (pneumocystosis, miliary tuberculosis) are excluded from ILDs of identified cause. Idiopathic interstitial pneumonias (IIPs) are most often sporadic, but familial cases constitute up to 2–20% of cases. These cases remain classified as IIPs despite the genetic predisposition. In addition to that classification, several rare histologic patterns of ILDs have been described, including acute fibrosing and organising pneumonia (AFOP) and bronchiolocentric patterns of interstitial pneumonia. These rare patterns are not considered as distinct entities of IIPs. The term “non-specific interstitial pneumonia” can apply to a distinct disease classified amongst IIPs (idiopathic non-specific interstitial pneumonia), or a pulmonary histologic pattern that can also be encountered in diverse ILDs of known cause, or even in other IIPs. ARDS: acute respiratory distress syndrome; BCG: bacillus Calmette–Guérin; CTDs: connective tissue diseases; HIV: human immunodeficiency virus; TNF α : tumour necrosis factor alpha.

and exercise-induced desaturation are all major prognostic factors in ILDs, alongside the extent of fibrosis on HRCT (particularly with a honeycombing pattern) and the presence of precapillary PH [22, 28–31].

Resting pulmonary function tests (PFTs) in ILDs

PFTs are essential to the diagnosis and to assess disease severity, prognosis and response to therapy. They typically show a low diffusion capacity of the lungs for carbon monoxide (D_{LCO}), associated with a restrictive ventilatory defect (RVD) with reduction of total lung capacity (TLC) and vital capacity (VC). Forced expiratory volume in one second (FEV_1)/VC ratio is often normal or even increased [19, 32–35]. Pathophysiological mechanisms for D_{LCO} changes in ILDs are almost always intertwined: \dot{V}_A/\dot{Q} mismatch being the main factor, in combination with alveolar capillary membrane thickening, reduction in gas exchange surface due to RVD and/or rarefaction of the pulmonary capillary bed. Therefore, D_{LCO} alteration is generally the first anomaly to be observed, decreasing to a greater extent than other functional variables when expressed as a percentage of reference values. Gas exchange impairment leads to widened alveolar–arterial oxygen pressure difference ($P_{(A-a)O_2}$) and hypoxaemia, first at exercise and ultimately at rest when D_{LCO} has severely declined [32–39]. Abnormal respiration mechanics, with increased lung recoil pressure and decreased lung compliance, are responsible for lung volume reduction. Depending on the criteria used, airway obstruction has been described in 8.8% to 57% of sarcoidosis patients [40–42]. Obstructive ventilatory defect (OVD), as defined by an excessively decreased FEV_1 /VC ratio, can also occur in other ILDs with particular airway involvement: rheumatoid arthritis, Sjögren's syndrome or inflammatory bowel disease associated ILD, HP, PLCH, LAM, silicosis, chronic eosinophilic pneumonia, respiratory bronchiolitis-ILD and chronic beryllium disease. OVD can occur independently or associated with RVD, such patients with mixed ventilatory defect tend to exhibit relatively preserved TLC and residual volume. In patients with combined pulmonary fibrosis and emphysema, the FEV_1 /VC ratio is only

reduced in cases of major emphysema extent. Despite relatively preserved lung volumes, these patients characteristically present with a severe, out-of-proportion, decrease in D_{LCO} [35, 43].

Exercise pathophysiology and CPET in ILDs

Resting PFTs cannot always predict exercise performance in individual ILD patients [37, 44, 45]. The six-minute walk test and CPET are valuable to assess functional status and detect precocious alteration in gas exchange. CPET is often mandatory for setting the exercise training intensity for pulmonary rehabilitation. CPET also helps to decipher the mechanisms of dyspnoea and exercise limitation of unclear origin, especially when PFTs and transthoracic echocardiogram (TTE) are either normal or both impaired. This is all the more important in ILDs with potential extrapulmonary involvement (sarcoidosis, CTDs) or when deconditioning with peripheral muscle weakness is suspected, which is a frequent situation in chronic lung diseases [5, 46–50]. Moreover, cardiovascular comorbidities are known to be frequent in IPF patients [51–53]. Given the huge variety of reasons for functional impairment, and the numerous modalities of decline, with many potential clinical and therapeutic questions, CPET positioning and timing during the course of ILDs is not unique [5, 47, 50]. Even if the minimal clinically important difference is unclear for CPET variables, repeated assessment is feasible and could be of great help in personalised medical decisions [54], especially as it can identify the mechanisms of improvement or deterioration. Data are scarce on this topic, but serial CPETs were used to assess the benefits of some pharmacological or non-pharmacological interventions, such as pulmonary rehabilitation [55–58].

Compared to age- and sex-matched healthy subjects, ILD patients regularly harbour a decrease in maximal O_2 uptake (peak \dot{V}_{O_2}) and maximal work rate (WR) (table 1) [5, 6, 46–50]. Indeed, various mechanisms can jointly contribute to that limitation, as ILDs induce numerous changes in physiologic and sensory responses to exercise (figure 2) [59–62]. Patients with ILD often hyperventilate at rest and during exercise, as demonstrated by a low P_{aCO_2} [39, 63]. Reduced lung compliance, with increased elastic loading on respiratory muscles and lung elastic recoil, alongside with stimulation of thoracic mechanoreceptors, limits the rise in V_T below 50–60% of maximal VC, leading to a characteristic shallow breathing pattern with high respiratory frequency (f_R). A low or absent breathing reserve (BR) at peak exercise frequently ensues [59, 60, 64–67]. Although the reduction in V_T is an effective strategy to minimise the inspiratory elastic work of breathing during exercise, the compensatory tachypnoea increases V_D . Also, impaired alveolar capillary diffusing capacity, low \dot{V}_A/\dot{Q} regions and reduced mixed O_2 venous partial pressure (P_{vO_2}) lead to exercise-induced hypoxaemia, P_{aO_2} being inversely proportional to WR [37, 39, 59, 61, 68, 69]. Both dynamic restrictive mechanical constraints and hypoxaemia-induced stimulation of peripheral chemoreceptors favour alveolar hyperventilation. In addition to \dot{V}_A/\dot{Q} mismatch, it results in ventilatory inefficiency: high V_D/V_T ratio (remaining abnormally stable or even increasing in exercising ILD patients) and increased \dot{V}_E/\dot{V}_{CO_2} relationship (at any given level of O_2 consumption). Increased pulmonary vascular resistance during exercise, from hypoxic pulmonary vasoconstriction and capillary bed remodelling or destruction, also participates in the alteration of ventilatory efficiency by increasing effective V_D [39, 59, 61, 67, 68, 70, 71]. Dynamic hyperinflation (DH), *i.e.* a decrease in inspiratory capacity during exercise, was documented in ILDs involving airways, such as LAM, PLCH and HP [72–75]. Since DH has been demonstrated in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension [76, 77], it could theoretically be present in patients with ILD and associated PH, but this issue has not yet been investigated. Several of the aforementioned pathophysiological mechanisms may be intertwined in a single individual, and all of them can be responsible for an elevated ventilatory neural drive, at any given WR, largely explaining the level of exertional breathlessness in ILD patients [67, 78–81]. An example of CPET can be found in figure 3. Importantly, cycling frequently underestimates the severity of exercise-related hypoxaemia in ILD patients.

Skeletal muscle dysfunction (SMD) is another important feature contributing to dyspnoea and exercise limitation in patients with various ILDs [82–86]. Not only quadriceps muscle strength, endurance and/or resistance to fatigue are reduced in ILDs compared to healthy individuals, but SMD seems to be more important in IPF than in COPD [87]. Indeed, leg discomfort is commonly recounted by ILD patients while exercising [57, 88, 89]. On the other hand, clinical significance of potential respiratory muscle impairment is debated. Diaphragmatic dysfunction can be encountered in advanced stages, but peripheral muscle weakness often seems to prevail [90]. Increased work of breathing and ventilatory inefficiency are thought to equate to chronic loading of respiratory muscles, which could preserve their function. All in all, the precise mechanisms of SMD in ILDs are still poorly understood. Several factors are suspected to participate: physical inactivity, ageing, malnutrition, arterial hypoxaemia resulting in tissue hypoxia, systemic inflammatory and oxidative stress, steroid myopathy, and/or direct insult by systemic disease [91, 92].

TABLE 1 Common cardiopulmonary exercise testing features in patients with interstitial lung disease (ILD) compared to other cardiopulmonary conditions

	ILD	COPD	CHF	PH	Deconditioning
Peak \dot{V}_{O_2}	Reduced	Reduced	Reduced	Reduced	Reduced
Peak WR	Reduced	Reduced	Reduced	Reduced	Reduced
\dot{V}_{O_2} at VTh	Normal or low	Normal or low	Low (early VTh)	Low (early VTh)	Low (early VTh)
$\Delta\dot{V}_{O_2}/\Delta WR$	Normal or low	Likely normal	Reduced ++	Reduced	Reduced
Maximal \dot{V}_{O_2}/HR (oxygen pulse)	Likely normal	Likely normal	Reduced ++	Reduced	Reduced
Peak HR	Likely reduced	Likely reduced	Normal or low	Likely normal	Normal
$\Delta HR/\Delta\dot{V}_{O_2}$	Variable	Variable	Elevated	Elevated	Elevated
BR	Reduced	Reduced	Normal	Normal	Normal
Peak f_R	Accelerated ++	Normal or accelerated	Normal or accelerated	Normal or accelerated	Normal or accelerated
Maximal V_T	Reduced	Likely reduced	Likely normal	Normal or reduced	Likely normal
\dot{V}_E/\dot{V}_{CO_2} at VTh	Elevated ++	Variable	Elevated	Elevated ++	Normal or elevated
\dot{V}_E/\dot{V}_{O_2} at VTh	Elevated ++	Variable	Elevated	Elevated ++	Normal or elevated
P_{ETCO_2}	Low	Variable, likely rising	Normal or low plateau	Low and decreasing	Normal
S_{aO_2}	Reduced ++	Reduced	Normal	Reduced ++	Normal
P_{aO_2}	Reduced ++	Reduced	Likely normal	Reduced ++	Normal
Peak $P_{(A-a)O_2}$	Widened ++	Widened	Likely normal	Widened ++	Normal
Peak V_D/V_T	High ++ sometimes not decreasing	High sometimes not decreasing	Normal or high	High ++ likely increasing	Likely normal
Other features	More severe hypoxaemia on walking than cycling	Frequent dynamic hyperinflation	Possible oscillatory breathing	Positive $P_{(a-ET)CO_2}$ during exercise	When severe, difficult to differentiate from cardiocirculatory limitation

Depending on the severity of underlying disease, pathologic features may not all be present in a given ILD patient. Conversely, associated comorbidities, obesity and/or negative inotropic drugs may result in mixed limitation pattern. ++ signs indicate potential higher variation from normal values. BR: breathing reserve; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; f_R : respiratory frequency; HR: heart rate; $P_{(A-a)O_2}$: alveolar–arterial oxygen pressure difference; $P_{(a-ET)CO_2}$: arterial–end tidal carbon dioxide pressure difference; P_{aO_2} : arterial oxygen partial pressure; P_{ETCO_2} : end-tidal carbon dioxide partial pressure; PH: pulmonary hypertension; S_{aO_2} : oxygen saturation; \dot{V}_{CO_2} : carbon dioxide output; V_D : dead space; \dot{V}_E : total ventilation; \dot{V}_{O_2} : oxygen uptake; V_T : tidal volume; VTh: first ventilatory threshold (anaerobic threshold); WR: work rate.




FIGURE 2 Mechanisms of exercise limitation in interstitial lung diseases. The combination of increased dead space and alveolar hyperventilation results in an abnormally elevated \dot{V}_E/\dot{V}_{CO_2} ratio. Ventilatory inefficiency and impairment of pulmonary gas exchange are key mechanisms of dyspnoea and exercise intolerance in patients with interstitial lung diseases (ILDs). Some ILDs may present with specific neuromuscular disorders (e.g. in sarcoidosis or connective tissue diseases) or heart involvement (e.g. in sarcoidosis or systemic sclerosis). Additionally, associated cardiovascular comorbidities are common (e.g. in idiopathic pulmonary fibrosis). \dot{V}_A/\dot{Q} : ventilation/perfusion.

Diagnostic utility of ventilatory efficiency in ILDs

Assessment of functional impairment (the example of sarcoidosis)

CPET may be useful to detect precocious functional impact in the context of ILD. Exercise limitation, as defined by peak $\dot{V}_{O_2} < 84\%$ of predicted value, affects 50–88% of sarcoidosis patients taken as a whole [93, 94]. But even those with still normal resting PFTs can harbour reduced peak \dot{V}_{O_2} [44, 45] or ventilatory inefficiency with abnormally increased \dot{V}_E/\dot{V}_{CO_2} [95]. In a US prospective study that included 39 patients with biopsy-proven sarcoidosis, ATHOS *et al.* [96] reported that disease staging by chest radiography was the best overall predictor of exercise performance. However, several other studies failed to find a correlation between disease staging and peak \dot{V}_{O_2} [95, 97, 98]. Along the same lines, although ventilatory inefficiency seems to be a sensitive marker of early functional impairment in sarcoidosis, no correlation was found in these studies between disease staging and \dot{V}_E/\dot{V}_{CO_2} , measured at VTh or at peak exercise [95–98]. One possible explanation is that organs other than lungs can be involved in sarcoidosis and alter the ventilatory response to exercise. Still, MAGRI *et al.* [99] found that the $\dot{V}_E-\dot{V}_{CO_2}$ slope was negatively correlated with resting D_{LCO} ($r = -0.85$; $p < 0.001$) and positively correlated with the change in arterial O_2 saturation (ΔS_{aO_2}) between rest and peak exercise ($r = 0.68$; $p < 0.001$) in 30 patients with stage 2–4 sarcoidosis. In the work by MILLER *et al.* [95], 78% of sarcoidosis patients with altered D_{LCO} had an abnormally elevated $\dot{V}_E/\dot{V}_{CO_2} > 34$ at VTh (mean: 45 ± 9) versus only 38% of those with normal D_{LCO} . Finally, in a more recent monocentric prospective work with 83 sarcoidosis patients, KALLIANOS *et al.* [100] found that \dot{V}_E/\dot{V}_{CO_2} at VTh progressively increased from stage 1 to stage 4 groups. Interestingly, a principal component analysis showed that elevated \dot{V}_E/\dot{V}_{CO_2} , peak \dot{V}_E/\dot{V}_{O_2} and V_D/V_T , all markers of inappropriate ventilatory response to exercise, were correlated with radiographic stage and with the presence of extrapulmonary locations. One limit of this study, however, was that it included only nine patients with stage 4 sarcoidosis.

global pattern of exercise response must be taken into account [5, 9]. Yet, in a Canadian cross-sectional study comparing 16 patients with mild-to-moderate ILD (mean VC: $73\pm 12\%$ of predicted value; mean TLC: $64\pm 10\%$; mean D_{LCO} : $44\pm 12\%$) to 16 sex- and age-matched patients with mild-to-moderate COPD (mean FEV₁: $63\pm 22\%$; mean D_{LCO} : $62\pm 22\%$) and 16 healthy subjects, FAISAL *et al.* [67] found that ventilatory inefficiency was significantly greater in ILD patients than in COPD patients, and even greater than in controls: 33 ± 5 versus 31 ± 4 and 27 ± 3 for \dot{V}_E/\dot{V}_{CO_2} nadir, respectively ($p<0.05$). These results were identical regardless of the calculation method (\dot{V}_E/\dot{V}_{CO_2} at rest, $\dot{V}_E-\dot{V}_{CO_2}$ slope, peak \dot{V}_E/\dot{V}_{CO_2}). Nevertheless, KISAKA *et al.* [101] found no difference between eight ILD patients and nine COPD patients when measuring \dot{V}_E/\dot{V}_{CO_2} at VTh: 36 ± 5 versus 37 ± 8 , as compared to 27 ± 3 in nine healthy controls. Six patients with pulmonary vasculopathy were also enrolled and they harboured the greatest \dot{V}_E/\dot{V}_{CO_2} at VTh (43 ± 5).

Given the particular sensitivity of CPET, HAGMEYER *et al.* [102] hypothesised that it could perhaps help to distinguish between two IIPs in the early course of the disease. In a prospective monocentric study, they compared exercise variables of 27 mild-to-moderate untreated IIPs, divided into two groups: 14 patients with IPF and 13 with iNSIP. They reported a significantly lower mean peak $\dot{V}O_2$ in IPF patients ($74\pm 31\%$ versus $99\pm 15\%$; $p=0.01$) and a significantly higher mean \dot{V}_E/\dot{V}_{CO_2} at any given level of O₂ consumption (e.g. 50 ± 14 versus 38 ± 6 at VTh; $p=0.01$). Nonetheless, one should remain cautious before integrating these findings into a diagnostic tree of IIPs. In fact, mean forced VC (FVC) was lower in IPFs ($65\pm 12\%$ versus $80\pm 23\%$), suggesting a more important alteration of lung compliance in this group, but no indication was given about f_R , although \dot{V}_E/\dot{V}_{CO_2} at VTh is presumably correlated with f_R at peak exercise in IIPs [103]. IPF patients also tended to exhibit a wider mean peak $P_{(A-a)O_2}$ (65 ± 11 mmHg versus 55 ± 14 mmHg), which could have participated in an accelerated f_R . Lastly, mean D_{LCO} tended to be lower in IPFs ($52\pm 22\%$ versus $62\pm 16\%$), especially since \dot{V}_E/\dot{V}_{CO_2} values differed amongst D_{LCO} quartiles; this difference could have accounted in part for a pulmonary vascular involvement that was not evaluated.




FIGURE 4 Examples of ventilatory efficiency slope ($\dot{V}_E-\dot{V}_{CO_2}$ slope) in a healthy subject presenting with a peak oxygen uptake ($\dot{V}O_2$) of $38\text{ mL}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$ (black line and rhomboid), a patient with pulmonary sarcoidosis presenting with a peak $\dot{V}O_2$ of $19\text{ mL}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$ (violet line and circles), a patient with pulmonary arterial hypertension (PAH) presenting with a peak $\dot{V}O_2$ of $18\text{ mL}\cdot\text{min}^{-1}\cdot\text{kg}^{-1}$ (red line and triangles) and a patient with idiopathic pulmonary fibrosis (IPF) presenting with a peak $\dot{V}O_2$ of $19\text{ mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (blue line and squares).

Early detection of pneumoconiosis in patients at risk

The assessment of ventilatory efficiency could play a role in monitoring patients exposed to inhaled mineral dust. DUVENKAMP *et al.* [104] compared 20 former coal miners with anthracosilicosis to 24 healthy volunteers and showed that mean \dot{V}_E/\dot{V}_{CO_2} at a submaximal WR of 50 watts was abnormally elevated in patients (39 ± 5 versus 31 ± 4 ; $p < 0.0001$) and was not correlated with the radiological grading of the disease. In a later French study of 38 patients with mild-to-moderate anthracosilicosis, all complaining of dyspnoea and divided into four groups in accordance with resting PFTs, FAVRE *et al.* [105] found a ventilatory inefficiency across all groups, including 21 patients with normal resting PFTs (mean peak \dot{V}_E/\dot{V}_{CO_2} in the normal PFT group: 39 ± 8). Peak \dot{V}_E/\dot{V}_{CO_2} was negatively correlated with D_{LCO} and positively correlated with ΔS_{aO_2} . One proposed reason why CPET was more sensitive than PFTs was that cardiac limitation (mixed or isolated) was involved in 12 (31%) of the patients having completed maximal exercise. In some coal miners, ventilatory inefficiency could also reveal the presence of small airway dysfunction [106]. Somewhat analogous observations were made with asbestosis: one German study compared 19 patients with former occupational asbestos exposure and variable resting PFTs to 24 healthy subjects; mean \dot{V}_E/\dot{V}_{CO_2} was higher in patients than in controls, but no correlation was found between ventilatory insufficiency and radiological severity of the disease [107].

Non-invasive diagnosis of coexisting PH

More importantly, patients with ILD are at high risk of developing PH. Guidelines have proposed risk stratification based on CPET variables, including peak \dot{V}_{O_2} , \dot{V}_E/\dot{V}_{CO_2} and end-tidal CO_2 partial pressure (P_{ETCO_2}), to evaluate patients with suspected PAH, either idiopathic or CTD-related. ILD patients with disproportionate \dot{V}_E/\dot{V}_{CO_2} must be suspected of pulmonary vasculopathy as well: in the context of ILD, PH may worsen pulmonary gas exchange and exacerbate the already exaggerated ventilatory response to exercise [15, 108, 109]. Specifically, in IPF patients, at least four studies, including two with prospective designs, have shown that \dot{V}_E/\dot{V}_{CO_2} was the best functional variable able to predict the coexistence of PH [110–113]. In another retrospective monocentric series of lung transplant candidates with various severe ILDs (almost half of them non-IPF), peak \dot{V}_E/\dot{V}_{CO_2} , P_{ETCO_2} and resting D_{LCO} were significantly associated with PH [114]. Ventilatory inefficiency was also assessed in a Brazilian prospective monocentric study of 32 PLCH patients with subsequent CPET and right heart catheterisation (RHC). The 13 (41%) patients with coexisting PH showed worse resting PFTs (FEV_1 , D_{LCO}) and tended to have a greater $\dot{V}_E-\dot{V}_{CO_2}$ slope (38 ± 15 versus 30 ± 5 ; $p=0.07$), but this last result was not statistically significant because of the small population size and large inter-subject variability [74]. In a prospective monocentric study with 27 mild-to-moderate ILDs (mean FVC: $68\pm 3\%$; mean D_{LCO} : $45\pm 5\%$), amongst which 14 (52%) were IPFs, DEGANI-COSTA *et al.* [115] performed invasive haemodynamic measurements during exercise to explore pulmonary vascular dysfunction (PVD), defined in accordance with the ratio between mean pulmonary artery pressure and cardiac output (mPAP–Q C slope). Although only seven patients had PH with elevated mPAP ≥ 25 mmHg at rest, PVD during exercise was identified in 15, harbouring higher \dot{V}_E/\dot{V}_{CO_2} at VTh than patients without PVD (45 ± 2 versus 38 ± 1 ; $p=0.015$), and higher peak V_D/V_T (39 ± 2 versus 30 ± 2 ; $p=0.008$).

In the particular case of systemic sclerosis (SSc), PAH may occur even without associated ILD. In SSc patients without respiratory limitation at exercise (normal BR at peak \dot{V}_{O_2}), high \dot{V}_E/\dot{V}_{CO_2} (at VTh or at maximal exercise) and decreasing P_{ETCO_2} from start of exercise to VTh were said to discriminate pulmonary vasculopathy from left ventricular dysfunction [116, 117]. In the US prospective series from DUMITRESCU *et al.* [116], which included 28 SSc patients with echocardiographic systolic pulmonary artery pressure (sPAP) ≤ 35 mmHg, an early pulmonary vasculopathy profile was identified in eight (62%) out of the 13 patients with ILD on HRCT (ILD-SSc). Nevertheless, these studies chose to solely characterize the predominant mechanism of exercise limitation for each patient. On the other side, a French retrospective multicentric study by MARTIS *et al.* [118], with 27 SSc patients having performed CPET, revealed that a combination of putative mechanisms was involved in 19 cases (70%). CPET found an ILD pattern in 16 patients (60%), which was 78% concordant with HRCT observations. Among the 10 patients referred for RHC, CPET variables indicating a pulmonary vasculopathy were more concordant with RHC than with TTE. Indeed, a good correlation between RHC and CPET variables, including \dot{V}_E/\dot{V}_{CO_2} , was previously described in SSc [119]. In combination with the DETECT screening algorithm (associating PFTs, biological markers and TTE in SSc patients with $D_{LCO} < 60\%$ and a disease duration > 3 years) [120], a $\dot{V}_E-\dot{V}_{CO_2}$ slope > 36 was suggested to be able to diminish the need for RHC referral, given its excellent sensitivity and negative predictive value. However, this threshold must be confirmed for ILD-SSc patients, since this Italian prospective multicentric cohort with 96 SSc patients included only seven with mild-to-intermediate lung fibrosis on HRCT [121].

The presence of coexisting PH in a patient with ILD and/or SSc is of high prognostic significance, and ventilatory inefficiency has been shown to be associated with worse outcomes in various configurations.

Prognostic implications of ventilatory inefficiency in ILDs

Many correlations were uncovered in the literature between survival and CPET variables, indicating that exercise limitation has a tremendous effect on ILD patients. In a US monocentric study that retrospectively analysed 117 patients with newly diagnosed IPF, FELL *et al.* [122] were the first to report that baseline peak $\dot{V}_{O_2} < 8.3 \text{ ml} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ was independently associated with a threefold increase in mortality. This association was later confirmed in a German multicentric cohort (retrospective analysis of prospectively collected data), with 135 IPF patients having performed PFTs, CPET and RHC, in which peak \dot{V}_{O_2} was the only functional variable independently predictive of transplant-free survival. Yet, the most powerful prognosticator was the presence of PH. \dot{V}_E/\dot{V}_{CO_2} was tightly associated with PH (area under receiver operating characteristic curve: 0.94 (0.89–0.98)), thus it was not retained as an independent marker of mortality in multivariate analysis [112]. Several other studies with retrospective designs concerning IPF patients [123–125] or lung transplantation candidates with various ILDs [126, 127] showed that \dot{V}_E/\dot{V}_{CO_2} was a mortality predictor at 1 or 3 years in univariate analysis, but not in final multivariate models. In a Japanese study of 41 IPF patients by MIKI *et al.* [123] (mean VC: $69 \pm 19\%$; mean D_{LCO} : $44 \pm 15\%$; mean peak \dot{V}_E/\dot{V}_{CO_2} : 52 ± 13), peak \dot{V}_E/\dot{V}_{CO_2} was the CPET variable most closely correlated with peak \dot{V}_{O_2} ($r = -0.7$; $p < 0.0001$), and was also correlated with P_{aO_2} slope, which was itself independently associated with mortality. Interestingly, in the work of WALLAERT *et al.* [124] with 63 IPF patients, among the numerous functional prognostic markers identified in univariate analysis, $TLC < 65\%$ and \dot{V}_E/\dot{V}_{O_2} at $V_{Th} > 45$ were independently predictive of 3-year transplant-free survival, that is to say another CPET variable very similar to \dot{V}_E/\dot{V}_{CO_2} .

Finally, \dot{V}_E/\dot{V}_{CO_2} was found to be independently associated with mortality in two prospective monocentric series. The first one included 25 treatment-naïve patients with mild-to-moderate IPF (mean FVC: $78 \pm 22\%$; mean D_{LCO} : $46 \pm 15\%$; mean \dot{V}_E/\dot{V}_{CO_2} slope: 40 ± 14) and slight-to-moderately severe dyspnoea. \dot{V}_E/\dot{V}_{CO_2} slope (hazard ratio: 1.09 (1.04–1.15)) and peak \dot{V}_{O_2} (hazard ratio: 0.75 (0.6–0.95)) were the most potent predictors of survival [128]. Interestingly, \dot{V}_E/\dot{V}_{CO_2} slope was the CPET variable best correlated with dyspnoea on the modified Medical Research Council (mMRC) scale ($r = 0.73$; $p < 0.001$) [89], whereas the mMRC scale had previously been showed to independently predict mortality [129, 130]. In the second series, VAINSELBOIM *et al.* [38, 131] included 38 stable, but not incident, IPFs (median FVC: 68 (37–109); median D_{LCO} : 50 (23–91); median \dot{V}_E/\dot{V}_{CO_2} slope: 43 (39–49)). Patients were subsequently randomised into two groups to assess the effects of a supervised 12-week exercise training program. As there was no difference in transplant-free survival at 40 months between both exercise training and control groups, patients were all analysed together for other prognostic factors. \dot{V}_E/\dot{V}_{CO_2} at $V_{Th} > 34$, \dot{V}_E/\dot{V}_{O_2} nadir > 34 , peak $\dot{V}_{O_2} \leq 13.8 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, V_T reserve $\leq 0.48 \text{ L} \cdot \text{breath}^{-1}$ and peak WR < 62 watts were associated with increased mortality or lung transplantation [131]. Exercise training significantly improved peak \dot{V}_{O_2} and \dot{V}_{O_2} at V_{Th} , but not peak \dot{V}_E/\dot{V}_{CO_2} [86]. This lack of effect of exercise training on \dot{V}_E/\dot{V}_{CO_2} was also observed in another study with 21 worsening IPFs [132].

It is not very surprising that \dot{V}_E/\dot{V}_{CO_2} seems to represent a reliable prognostic factor in ILDs, since it reflects the potential convergence of several pathophysiological mechanisms involved in disease progression and ultimately prognosis. Indeed, excessive hyperventilation at exercise may result from dynamic mechanical constraints secondary to lung restriction, exercise-induced hypoxaemia, pulmonary vasculopathy with increased V_D and other poorly understood peripheral factors. Incidentally, one weakness of some of the aforementioned studies is that pulmonary vasculopathy was not always assessed. A recent literature systematic review identified other confounding factors, including methodological heterogeneity and selective reporting bias [133]. Another limitation is that “baseline” CPET was actually often performed at different stages of the disease, since not only newly diagnosed ILDs were included. Moreover, very few studies have investigated the value of longitudinal data from subsequent CPETs.

Several studies have explored the links between PH, exercise limitation and prognosis in ILDs. In these patients, associated PH was demonstrated to significantly impair maximal aerobic capacity [74, 110, 112–114], sometimes only when PH was classified as severe [111]. Additionally, \dot{V}_E/\dot{V}_{CO_2} was found to correlate with dyspnoea during CPET (Borg scale) [110] and with PH severity, as assessed by sPAP measured by TTE, with correlation coefficients varying from 0.61 to 0.87 [110, 111, 113]. In another series, peak \dot{V}_E/\dot{V}_{CO_2} and peak P_{ETCO_2} were the two variables best correlated with mPAP measured during RHC [114, 134]. In the monocentric work of VAN DER PLAS *et al.* [113], in which 38 prospectively enrolled IPF patients performed CPET and TTE, the optimal cut-off value for predicting a resting sPAP ≥ 40 mmHg was a \dot{V}_E/\dot{V}_{CO_2} at $V_{Th} > 45$. This cut-off value also proved to be a good prognosis marker, since mean survival was 81.3 ± 14.1 months in the 24 patients with \dot{V}_E/\dot{V}_{CO_2} at $V_{Th} \leq 45$ versus 21 ± 4.9 months in the 14 patients with \dot{V}_E/\dot{V}_{CO_2} at $V_{Th} > 45$ ($p = 0.001$). Conversely, it is of note that the cut-off value of 40 mmHg for resting sPAP was not able to identify two groups with different prognosis ($n = 27$ for sPAP < 40 mmHg and $n = 11$ for sPAP ≥ 40 mmHg) [113].

Concerning SSc, an important German multicentric study by EWERT *et al.* [135] retrospectively analysed the outcome of 210 patients having performed CPET. Amongst them, 74 (35%) had ILD on HRCT, rated as ILD limited to less than 20% of lung surface for 42 (20%) or extensive ILD for 32 (15%). Simultaneously, RHC was performed in 139 (66%), leading to a diagnosis of PAH in 52 (25%). In multivariate analysis, $\dot{V}_E-\dot{V}_{CO_2}$ slope (hazard ratio: 0.9 (0.83–0.98)) and peak \dot{V}_{O_2} (hazard ratio: 0.87 (0.81–0.94)) were significant predictive factors of long-term survival (median follow-up: 7.7 years), alongside age, FVC and Krogh factor (K_{CO} , *i.e.* D_{LCO} per alveolar volume). Optimal cut-off values with the highest discriminative power were 35 for $\dot{V}_E-\dot{V}_{CO_2}$ slope and 64.5% of predicted value for peak \dot{V}_{O_2} [135]. In another recent Italian monocentric study, Rosato *et al.* [136] prospectively included 45 SSc patients who subsequently performed baseline CPET, PFTs, TTE and HRCT (median lung surface with HRCT pattern of ILD on CALIPER analysis: 9.8% (7.3–16.1); median FVC: 102% (89–109); median D_{LCO} : 77% (71–81); median $\dot{V}_E-\dot{V}_{CO_2}$ slope: 29 (28–32)). Then, PFTs and TTE were annually repeated during the 5-year follow-up. The study population was divided into two groups: 37 (82%) with normal $\dot{V}_E-\dot{V}_{CO_2}$ slope at baseline and eight (18%) with baseline ventilatory inefficiency as defined by $\dot{V}_E-\dot{V}_{CO_2}$ slope ≥ 35 . Baseline ventilatory inefficiency was a marker of ILD progression and pulmonary vasculopathy, with a greater decline of FVC (9.6% (0.5–12.2) versus 2.4% (0.4–5.0); $p < 0.05$) and D_{LCO} (9.2% (6.4–16.6) versus 2.3% (0.5–5.2); $p < 0.01$), and a greater raise in sPAP (7.8 mmHg (5.2–14.2) versus –1.5 mmHg (–1––3); $p < 0.0001$) during follow-up. Moreover, in multivariate analysis, $\dot{V}_E-\dot{V}_{CO_2}$ slope was independently associated with the onset of a new major vascular complication, namely digital ulcers, PAH and scleroderma renal crisis (hazard ratio: 1.09 (1.02–1.2)). Lastly, $\dot{V}_E-\dot{V}_{CO_2}$ slope was the only significant independent prognostic factor of mortality from ILD at 5 years (hazard ratio: 1.27 (1.003–1.6)) and a $\dot{V}_E-\dot{V}_{CO_2}$ slope ≥ 35 was a prognostic factor of all-cause mortality at 5 years [136]. The same team had previously showed that, in SSc patients without obvious cardiopulmonary involvement, $\dot{V}_E-\dot{V}_{CO_2}$ slope was a marker of vascular kidney damage [137] and was significantly correlated with global disease activity and severity, as assessed by Disease Activity Index and Disease Severity Index ($r = 0.59$ and 0.73 , respectively; both $p < 0.0001$) [138].

Conclusion

ILDs are a devastating category of diseases, which can carry a poor prognosis in cases of progressive fibrosing pattern and/or associated PH. Exercise intolerance and exertional dyspnoea are key symptoms that contribute to curtailing and then avoiding physical activity, resulting in progressive deconditioning. The mechanisms of exercise intolerance in ILD patients are due to a combination of factors including altered pulmonary gas exchange, anomalies in pulmonary mechanics and cardiovascular function, as well as SMD. CPET can be a valuable tool to not only assist in diagnosis, determine the presence of comorbidities, objectively evaluate functional capacity, determine symptom severity, accurately prescribe exercise training and monitor disease progression or therapeutic response, but also generate valuable prognostic information and optimise the management of patients with ILD. Evidence concerning the clinical utility of ventilatory efficiency as a prognostic indicator in ILD is rapidly emerging and therefore promising.

Provenance: Commissioned article, peer reviewed.

Previous articles in this series: **No. 1:** Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exercise testing in the modern era. *Eur Respir Rev* 2021; 30: 200187. **No. 2:** Agnostoni P, Sciomer S, Palermo P, *et al.* Minute ventilation/carbon dioxide production in chronic heart failure. *Eur Respir Rev* 2021; 30: 200141. **No. 3:** Watson M, Ionescu MF, Sylvester K, *et al.* Minute ventilation/carbon dioxide production in patients with dysfunctional breathing. *Eur Respir Rev* 2021; 30: 200182. **No. 4:** Ward SA. Ventilation/carbon dioxide output relationships during exercise in health. *Eur Respir Rev* 2021; 30: 200160. **No. 5:** Collins SÉ, Phillips DB, Brotto AR, *et al.* Ventilatory efficiency in athletes, asthma and obesity. *Eur Respir Rev* 2021; 30: 200206. **No. 6:** Schaeffer MR, Guenette JA, Jensen D. Impact of ageing and pregnancy on the minute ventilation/carbon dioxide production response to exercise. *Eur Respir Rev* 2021; 30: 200225. **No. 7:** Weatherald J, Philipenko B, Montani D, *et al.* Ventilatory efficiency in pulmonary vascular diseases. *Eur Respir Rev* 2021; 30: 200214. **No. 8:** Neder JA, Berton DC, Phillips DB, *et al.* Exertional ventilation/carbon dioxide output relationship in COPD: from physiological mechanisms to clinical applications. *Eur Respir Rev* 2021; 30: 200190. **No. 9:** Hager A. Minute ventilation/carbon dioxide production in congenital heart disease. *Eur Respir Rev* 2021; 30: 200178. **No. 10:** Laveneziana P, Palange P. Ventilatory efficiency and its clinical and prognostic value in adults with cystic fibrosis. *Eur Respir Rev* 2021; 30: 200395.

Conflict of interest: T. Gille reports personal fees from Boehringer Ingelheim and Roche, and other funding from Oxyvie (oxygen provider), LVL Medical (oxygen provider) and VITALAIRE (oxygen provider), outside the submitted

work. P. Laveneziana reports personal fees from Novartis France, Chiesi France and Boehringer France, outside the submitted work.

References

- 1 King TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. *Am J Respir Crit Care Med* 2005; 172: 268–279.
- 2 Margaritopoulos GA, Romagnoli M, Poletti V, et al. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. *Eur Respir Rev* 2012; 21: 48–56.
- 3 Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases: number 6 in the series ‘personalised medicine in respiratory diseases’ edited by Renaud Louis and Nicolas Roche. *Eur Respir Rev* 2018; 27: 170117.
- 4 O’Donnell DE, Chau LKL, Webb KA. Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. *J Appl Physiol* 1998; 84: 2000–2009.
- 5 Sietsema KE, Sue DY, Stringer WW, et al. Wasserman & Whipp’s Principles of Exercise Testing and Interpretation. 6th edn. Philadelphia, Lippincott Williams & Wilkins, 2020.
- 6 Palange P, Ward SA, Carlsen K-H, et al. Recommendations on the use of exercise testing in clinical practice. *Eur Respir J* 2007; 29: 185–209.
- 7 Balady GJ, Arena R, Sietsema K, et al. Clinician’s guide to cardiopulmonary exercise testing in adults. *Circulation* 2010; 122: 191–225.
- 8 Radtke T, Crook S, Kaltsakas G, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. *Eur Respir Rev* 2019; 28: 180101.
- 9 Aguilaniu B, Wallaert B. From interpretation of cardiopulmonary exercise testing to medical decision. *Rev Mal Respir* 2013; 30: 498–515.
- 10 Ward S. Ventilation/carbon dioxide output relationships during exercise in health. *Eur Respir Rev* 2021; 30: 200160.
- 11 Jamnick NA, Pettitt RW, Granata C, et al. An examination and critique of current methods to determine exercise intensity. *Sports Med* 2020; 50: 1729–1756.
- 12 Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. *Eur Respir J* 2016; 47: 429–460.
- 13 Weatherald J, Sattler C, Garcia G, et al. Ventilatory response to exercise in cardiopulmonary disease: the role of chemosensitivity and dead space. *Eur Respir J* 2018; 51: 1700860.
- 14 Phillips DB, Collins SÉ, Stickland MK. Measurement and interpretation of exercise ventilatory efficiency. *Front Physiol* 2020; 11: 659.
- 15 Laveneziana P, Weatherald J. Pulmonary vascular disease and cardiopulmonary exercise testing. *Front Physiol* 2020; 11: 964.
- 16 Valeyre D, Duchemann B, Nunes H, et al. Interstitial lung diseases. In: Annesi-Maesano I, Lundbäck B, Viegi G, eds. ERS Monograph Respiratory Epidemiology. Sheffield, European Respiratory Society, 2014; pp. 79–87.
- 17 Sesé L, Khamis W, Jeny F, et al. Adult interstitial lung diseases and their epidemiology. *Presse Med* 2020; 49: 104023.
- 18 Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. *Eur Respir J* 2017; 50: 1602419.
- 19 ATS/ERS. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2002; 165: 277–304.
- 20 Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013; 188: 733–748.
- 21 Wells AU, Hirani N. Interstitial lung disease guideline. *Thorax* 2008; 63: v1–v58.
- 22 Jeny F, Brillet p-Y, Kim Y-W, et al. The place of high-resolution computed tomography imaging in the investigation of interstitial lung disease. *Expert Rev Respir Med* 2019; 13: 79–94.
- 23 Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2018; 198: e44–e68.
- 24 Cottin V, Wollin L, Fischer A, et al. Fibrosing interstitial lung diseases: knowns and unknowns. *Eur Respir Rev* 2019; 28: 180100.
- 25 George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respir Med* 2020; 8: 925–934.
- 26 Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med* 2019; 381: 1718–1727.
- 27 Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med* 2020; 8: 453–460.

- 28 O'Connell OJ, Egan JJ. The evaluation of disease severity/staging for prognosis. *In: Costabel U, Crestani B, Wells AU, eds. ERS Monograph Idiopathic Pulmonary Fibrosis. Sheffield, European Respiratory Society, 2016; pp. 97–105.*
- 29 Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. *Respir Res*; 2019; 20: 1–8.
- 30 Nunes H, Uzunhan Y, Gille T, *et al.* Pulmonary hypertension complicating interstitial and granulomatous lung diseases. *In: Humbert M, Souza R, Simonneau G, eds. Progress in Respiratory Research. Basel, S. Karger AG, 2012; pp. 178–198.*
- 31 Panagiotou M, Church AC, Johnson MK, *et al.* Pulmonary vascular and cardiac impairment in interstitial lung disease. *Eur Respir Rev* 2017; 26: 160053.
- 32 Denison D, Al-Hillawi H, Turton C. Lung function in interstitial lung disease. *Semin Respir Crit Care Med* 1984; 6: 40–54.
- 33 Robertson HT. Clinical application of pulmonary function and exercise tests in the management of patients with interstitial lung disease. *Semin Respir Crit Care Med* 1994; 15: 1–9.
- 34 Baydur A. Physiology of ILD: recent developments in understanding and in clinical application. *In: Sharma OP, ed. Interstitial Lung Diseases. New Delhi, Jaypee Brothers Medical Publishers; 2012; pp. 11–27.*
- 35 Miguel-Reyes JL, Gochicoa-Rangel L, Pérez-Padilla R, *et al.* Functional respiratory assessment in interstitial lung disease. *Rev Invest Clin* 2015; 67: 5–14.
- 36 Wagner PD, Dantzker DR, Dueck R, *et al.* Distribution of ventilation-perfusion ratios in patients with interstitial lung disease. *Chest* 1976; 69: 256–257.
- 37 Keogh BA, Lakatos E, Price D, *et al.* Importance of the lower respiratory tract in oxygen transfer. *Am Rev Respir Dis* 1984; 129: S76–S80.
- 38 Dunn TL, Watters LC, Hendrix C, *et al.* Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. *Am J Med* 1988; 85: 221–224.
- 39 Agustí AGN, Roca J, Gea J, *et al.* Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. *Am Rev Respir Dis* 1991; 143: 219–225.
- 40 Nunes H, Uzunhan Y, Gille T, *et al.* Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function. *Eur Respir J* 2012; 40: 750–765.
- 41 Valeyre D, Bernaudin J-F, Jeny F, *et al.* Pulmonary sarcoidosis. *Clin Chest Med* 2015; 36: 631–641.
- 42 Kouranos V, Ward S, Kokosi MA, *et al.* Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features. *Chest* 2020; 158: 2007–2014.
- 43 Wells AU, Margaritopoulos GA, Antoniou KM, *et al.* CPFE: distinctive and non-distinctive features. *In: Costabel U, Crestani B, Wells AU, eds. ERS Monograph Idiopathic Pulmonary Fibrosis. Sheffield, European Respiratory Society, 2016; pp. 175–185.*
- 44 Delobbe A, Perrault H, Maitre J, *et al.* Impaired exercise response in sarcoid patients with normal pulmonary function. *Sarcoidosis Vasc Diffuse Lung Dis* 2002; 19: 148–153.
- 45 Akkoca Ö, Celik G, Ulger F, *et al.* Exercise capacity in sarcoidosis. Study of 29 patients. *Med Clin* 2005; 124: 686–689.
- 46 Troy LK, Young IH, Lau EMT, *et al.* Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia. *Respirology* 2016; 21: 1005–1014.
- 47 Aguilaniu B. CPET and interstitial pulmonary disease: what for and how to make the best use of it? *La Lettre du Pneumologue* 2016; 19: 16–20.
- 48 Bonini M, Fiorenzano G. Exertional dyspnoea in interstitial lung diseases: the clinical utility of cardiopulmonary exercise testing. *Eur Respir Rev* 2017; 26: 160099.
- 49 Molgat-Seon Y, Schaeffer MR, Ryerson CJ, *et al.* Exercise pathophysiology in interstitial lung disease. *Clin Chest Med* 2019; 40: 405–420.
- 50 Molgat-Seon Y, Schaeffer MR, Ryerson CJ, *et al.* Cardiopulmonary exercise testing in patients with interstitial lung disease. *Front Physiol* 2020; 11: 832.
- 51 Nathan SD, Basavaraj A, Reichner C, *et al.* Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. *Respir Med* 2010; 104: 1035–1041.
- 52 Broder M, Change E, Papoyan E, *et al.* Risk of cardiovascular comorbidities in patients with idiopathic pulmonary fibrosis: analysis of Medicare data. *Eur Respir J* 2016; 48: 14953–14958.
- 53 Gille T, Didier M, Boubaya M, *et al.* Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis. *Eur Respir J* 2017; 49: 1601934.
- 54 Davis R, Dixon C, Millar A, *et al.* A role for cardiopulmonary exercise testing in detecting physiological changes underlying health status in Idiopathic pulmonary fibrosis: a feasibility study. *BMC Pulm Med* 2021; 21: 147.
- 55 Jackson RM, Glassberg MK, Ramos CF, *et al.* Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. *Lung* 2010; 188: 115–123.
- 56 Blanco I, Ribas J, Xaubet A, *et al.* Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis. *J Appl Physiol* 2011; 110: 638–645.

- 57 Schaeffer MR, Ryerson CJ, Ramsook AH, *et al.* Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. *Eur Respir J* 2017; 49: 1602494.
- 58 Tonelli R, Cocconcelli E, Lanini B, *et al.* Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. *BMC Pulm Med* 2017; 17: 130.
- 59 Anderson SD, Bye PT. Exercise testing in the evaluation of diffuse interstitial lung disease. *Aust NZ J Med* 1984; 14: 762–768.
- 60 Marciniuk DD, Watts RE, Gallagher CG. Dead space loading and exercise limitation in patients with interstitial lung disease. *Chest* 1994; 105: 183–189.
- 61 Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. *Chest* 1996; 109: 1566–1576.
- 62 Harris-Eze AO, Sridhar G, Clemens RE, *et al.* Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. *Am J Respir Crit Care Med* 1996; 154: 994–1001.
- 63 Hughes JM, Lockwood DN, Jones HA, *et al.* D_{LCO}/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. *Respir Physiol* 1991; 83: 155–166.
- 64 Renzi G, Milic-Emili J, Grassino AE. The pattern of breathing in diffuse lung fibrosis. *Bull Eur Physiopathol Respir* 1982; 18: 461–472.
- 65 Burdon JG, Killian KJ, Jones NL. Pattern of breathing during exercise in patients with interstitial lung disease. *Thorax* 1983; 38: 778–784.
- 66 DiMarco AF, Kelsen SG, Cherniack NS, *et al.* Occlusion pressure and breathing pattern in patients with interstitial lung disease. *Am Rev Respir Dis* 1983; 127: 425–430.
- 67 Faisal A, Alghamdi BJ, Ciavaglia CE, *et al.* Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. *Am J Respir Crit Care Med* 2015; 193: 299–309.
- 68 Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. *Chest* 1984; 85: 69–74.
- 69 Lamberto C, Nunes H, Le Toumelin P, *et al.* Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis: relation to exercise gas exchange. *Chest* 2004; 125: 2061–2068.
- 70 Weitzenblum E, Ehrhart M, Rasaholinjanahary J, *et al.* Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. *Respiration* 1983; 44: 118–127.
- 71 Agustí AG, Roca J, Rodriguez-Roisin R, *et al.* Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. *Eur Respir J* 1988; 1: 510–516.
- 72 Baldi BG, Albuquerque ALP, Pimenta SP, *et al.* Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. *Am J Respir Crit Care Med* 2012; 186: 341–348.
- 73 Rolland-Debord C, Fry S, Giovannelli J, *et al.* Physiologic determinants of exercise capacity in pulmonary Langerhans cell histiocytosis: a multidimensional analysis. *PLoS ONE* 2017; 12: e0170035.
- 74 Heiden GI, Sobral JB, Freitas CSG, *et al.* Mechanisms of exercise limitation and prevalence of pulmonary hypertension in pulmonary Langerhans cell histiocytosis. *Chest* 2020; 158: 2440–2448.
- 75 Dias OM, Baldi BG, Ferreira JG, *et al.* Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis. *ERJ Open Res* 2018; 4: 00043–02018.
- 76 Richter MJ, Voswinckel R, Tiede H, *et al.* Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. *Respir Med* 2012; 106: 308–313.
- 77 Laveneziana P, Garcia G, Joureau B, *et al.* Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. *Eur Respir J* 2013; 41: 578–587.
- 78 O'Donnell DE, Ora J, Webb KA, *et al.* Mechanisms of activity-related dyspnea in pulmonary diseases. *Respir Physiol Neurobiol* 2009; 167: 116–132.
- 79 Laveneziana P. Qualitative aspects of exertional dyspnea in patients with restrictive lung disease. *Multidiscip Respir Med* 2010; 5: 211–215.
- 80 Schaeffer MR, Ryerson CJ, Ramsook AH, *et al.* Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. *Eur Respir J* 2018; 51: 1701726.
- 81 Cournoyer J, Ramos CF, Sturgill B, *et al.* Effects of 100% oxygen during exercise in patients with interstitial lung disease. *Respir Physiol Neurobiol* 2020; 274: 103367.
- 82 Nishiyama O, Taniguchi H, Kondoh Y, *et al.* Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. *Chest* 2005; 127: 2028–2033.
- 83 Spruit MA, Thomeer MJ, Gosselink R, *et al.* Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. *Thorax* 2005; 60: 32–38.
- 84 Watanabe F, Taniguchi H, Sakamoto K, *et al.* Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. *Respir Med* 2013; 107: 622–628.
- 85 Mendoza L, Gogali A, Shrikrishna D, *et al.* Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. *Respirology* 2014; 19: 138–143.
- 86 Vainshelboim B, Oliveira J, Fox BD, *et al.* Physiological profile and limitations in exercise in idiopathic pulmonary fibrosis. *J Cardiopulm Rehabil Prev* 2016; 36: 270–278.

- 87 Koza R, Senjyu H, Jenkins SC, *et al.* Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. *Respiration* 2011; 81: 196–205.
- 88 Marciniuk DD, Sridhar G, Clemens RE, *et al.* Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. *J Appl Physiol* 1994; 77: 963–973.
- 89 Manali ED, Lyberopoulos P, Triantafyllidou C, *et al.* MRC chronic dyspnea scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. *BMC Pulm Med* 2010; 10: 32.
- 90 Walterspacher S, Schlager D, Walker DJ, *et al.* Respiratory muscle function in interstitial lung disease. *Eur Respir J* 2013; 42: 211–219.
- 91 Panagiotou M, Polychronopoulos V, Strange C. Respiratory and lower limb muscle function in interstitial lung disease. *Chron Respir Dis* 2016; 132: 162–172.
- 92 Marillier M, Bernard A-C, Verges S, *et al.* Oxygen supplementation during exercise improves leg muscle fatigue in chronic fibrotic interstitial lung disease. *Thorax* 2021; 76: 672–680.
- 93 Marcellis RGJ, Lenssen AF, de Vries J, *et al.* Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. *Curr Opin Pulm Med* 2013; 19: 524–530.
- 94 Strookappe B, Saketkoo LA, Elfferich M, *et al.* Physical activity and training in sarcoidosis: review and experience-based recommendations. *Expert Rev Respir Med* 2016; 10: 1057–1068.
- 95 Miller A, Brown LK, Sloane MF, *et al.* Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. *Chest* 1995; 107: 323–329.
- 96 Athos L, Mohler JG, Sharma OP. Exercise testing in the physiologic assessment of sarcoidosis. *Ann NY Acad Sci* 1986; 465: 491–501.
- 97 Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. *Chest* 2001; 120: 93–101.
- 98 Wallaert B, Talleu C, Wemeau-Stervinou L, *et al.* Reduction of maximal oxygen uptake in sarcoidosis: relationship with disease severity. *Respiration* 2011; 82: 501–508.
- 99 Magrì D, Mariotta S, Banfi C, *et al.* Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis. *Respir Med* 2013; 107: 1617–1624.
- 100 Kallianos A, Zarogoulidis P, Ampatzoglou F, *et al.* Reduction of exercise capacity in sarcoidosis in relation to disease severity. *Patient Prefer Adherence* 2015; 9: 1179–1188.
- 101 Kisaka T, Cox TA, Dumitrescu D, *et al.* CO₂ pulse and acid-base status during increasing work rate exercise in health and disease. *Respir Physiol Neurobiol* 2015; 218: 46–56.
- 102 Hagemeyer L, Herkenrath S, Anduleit N, *et al.* Cardiopulmonary exercise testing allows discrimination between idiopathic non-specific interstitial pneumonia and idiopathic pulmonary fibrosis in mild to moderate stages of the disease. *Lung* 2019; 197: 721–726.
- 103 de Martino M, Cobuccio R, Bruzzese D, *et al.* Exercise related ventilation dynamics and clinical correlates in patients with fibrotic idiopathic interstitial pneumonias. *Sarcoidosis Vasc Diffuse Lung Dis* 2016; 33: 157–165.
- 104 Duvenkamp I, Bauer TT, Schmidt EW, *et al.* Submaximal spiroergometric stress study in patients with mixed dust pneumoconiosis. *Pneumologie* 1998; 52: 171–177.
- 105 Favre M-N, Roche N, Januel B, *et al.* Exercise test and evaluation of exertional dyspnoea in former coal miners. *Rev Mal Respir* 2002; 19: 315–322.
- 106 Petsonk EL, Stansbury RC, Beeckman-Wagner L-A, *et al.* Small airway dysfunction and abnormal exercise responses. A study in coal miners. *Ann Am Thorac Soc* 2016; 13: 1076–1080.
- 107 Schneider J, Arhelger R, Funk M. Spiroergometric parameters at maximal exercise testing assessed functional respiratory impairment in asbestos-induced fibrosis. *Clin Respir J* 2014; 8: 175–184.
- 108 Guazzi M, Adams V, Conraads V, *et al.* Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. *Eur Heart J* 2012; 33: 2917–2927.
- 109 Weatherald J, Philipenko B, Montani D, *et al.* Ventilatory efficiency in pulmonary vascular disease. *Eur Respir Rev* 2021; 30: 200214.
- 110 Gläser S, Noga O, Koch B, *et al.* Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. *Respir Med* 2009; 103: 317–324.
- 111 Boutou AK, Pitsiou GG, Trigonis I, *et al.* Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. *Respirology* 2011; 16: 451–458.
- 112 Gläser S, Obst A, Koch B, *et al.* Pulmonary hypertension in patients with idiopathic pulmonary fibrosis – the predictive value of exercise capacity and gas exchange efficiency. *PLoS ONE* 2013; 8: e65643.
- 113 van der Plas MN, van Kan C, Blumenthal J, *et al.* Pulmonary vascular limitation to exercise and survival in idiopathic pulmonary fibrosis. *Respirology* 2014; 19: 269–275.
- 114 Armstrong HF, Thirapatarapong W, Dussault NE, *et al.* Distinguishing pulmonary hypertension in interstitial lung disease by ventilation and perfusion defects measured by cardiopulmonary exercise testing. *Respiration* 2013; 86: 407–413.
- 115 Degani-Costa LH, Leverage B, Digumarthy SR, *et al.* Pulmonary vascular response patterns during exercise in interstitial lung disease. *Eur Respir J* 2015; 46: 738–749.

- 116 Dumitrescu D, Oudiz RJ, Karpouzas G, *et al.* Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing. *PLoS ONE* 2010; 5: e14293.
- 117 Boutou AK, Pitsiou GG, Siakka P, *et al.* Phenotyping exercise limitation in systemic sclerosis: the use of cardiopulmonary exercise testing. *Respiration* 2016; 91: 115–123.
- 118 Martis N, Queyrel-Moranne V, Launay D, *et al.* Limited exercise capacity in patients with systemic sclerosis: identifying contributing factors with cardiopulmonary exercise testing. *J Rheumatol* 2018; 45: 95–102.
- 119 Dumitrescu D, Nagel C, Kovacs G, *et al.* Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. *Heart* 2017; 103: 774–782.
- 120 Coghlan JG, Denton CP, Grünig E, *et al.* Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis* 2014; 73: 1340–1349.
- 121 Santaniello A, Casella R, Vicenzi M, *et al.* Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis. *Rheumatology* 2020; 59: 1581–1586.
- 122 Fell CD, Liu LX, Motika C, *et al.* The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2009; 179: 402–407.
- 123 Miki K, Maekura R, Hiraga T, *et al.* Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. *Respir Med* 2003; 97: 482–490.
- 124 Wallaert B, Guetta A, Wemeau-Stervinou L, *et al.* Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis. *Rev Mal Respir* 2011; 28: 290–296.
- 125 King TE, Toozee JA, Schwarz MI, *et al.* Predicting survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2001; 164: 1171–1181.
- 126 Kawut SM, O’Shea MK, Bartels MN, *et al.* Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. *Respir Med* 2005; 99: 1431–1439.
- 127 Layton AM, Armstrong HF, Kim HP, *et al.* Cardiopulmonary exercise factors predict survival in patients with advanced interstitial lung disease referred for lung transplantation. *Respir Med* 2017; 126: 59–67.
- 128 Triantafyllidou C, Manali E, Lyberopoulos P, *et al.* The role of cardiopulmonary exercise test in IPF prognosis. *Pulm Med* 2013; 2013: 514817.
- 129 Manali ED, Stathopoulos GT, Kollintza A, *et al.* The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. *Respir Med* 2008; 102: 586–592.
- 130 Nishiyama O, Taniguchi H, Kondoh Y, *et al.* A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. *Eur Respir J* 2010; 36: 1067–1072.
- 131 Vainshelboim B, Oliveira J, Fox BD, *et al.* The prognostic role of ventilatory inefficiency and exercise capacity in idiopathic pulmonary fibrosis. *Respir Care* 2016; 61: 1100–1109.
- 132 Jackson RM, Gómez-Marín OW, Ramos CF, *et al.* Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. *Lung* 2014; 192: 367–376.
- 133 Barratt SL, Davis R, Sharp C, *et al.* The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. *ERJ Open Res* 2020; 6: 00027-2020.
- 134 Armstrong HF, Schulze PC, Bacchetta M, *et al.* Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation. *Respirology* 2014; 19: 675–682.
- 135 Ewert R, Ittermann T, Habedank D, *et al.* Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. *BMC Pulm Med* 2019; 19: 230.
- 136 Rosato E, Leodori G, Gigante A, *et al.* Reduced ventilatory efficiency during exercise predicts major vascular complications and mortality for interstitial lung disease in systemic sclerosis. *Clin Exp Rheumatol* 2020; 38: Suppl. 125, 85–91.
- 137 Gigante A, Romaniello A, Magrì D, *et al.* Correlation between intrarenal arterial stiffness and exercise tolerance in systemic sclerosis patients without renal and cardiopulmonary impairment: the role of the microvascular damage. *Int J Cardiol* 2015; 185: 122–124.
- 138 Rosato E, Romaniello A, Magrì D, *et al.* Exercise tolerance in systemic sclerosis patients without pulmonary impairment: correlation with clinical variables. *Clin Exp Rheumatol* 2014; 32: S-103–S-108.